Shenrui Bio has obtained global patent for detection of prostate cancer gene methylation March 14, 2016 Source: 39 Health Net Prostate cancer is the most common cancer in men. Men over the age of 60 are high-risk populations of prostate cancer. The older the patients, the higher the prevalence. In recent years, due to lifestyle changes, an aging population, and the prevalence of early cancer screening, the number of patients with prostate cancer in China has increased year by year. In 2012, China added 47,000 cases of prostate cancer, and about 23,000 prostate cancer patients died. To this end, early accurate diagnosis of prostate cancer has enormous clinical needs and industrial development space. At present, the traditional diagnostic method for prostate cancer is to detect the concentration of specific antigen (PSA) in serum, and to perform a needle biopsy on patients with high PSA. However, the main drawback of this method is that the specificity of PSA is poor (only 25%-40% when PSA 4-10ng/ml), other prostate diseases such as prostatitis and benign prostatic hyperplasia can also cause abnormal PSA concentration. Therefore, unnecessary puncture biopsy often occurs, causing great pain to the patient. Therefore, there is an urgent need to find a diagnostic marker for early prostate cancer with high sensitivity and specificity. The Institute of Genomics of the Chinese Academy of Sciences and the Shanghai Changhai Hospital of the Second Military Medical University collaborated to analyze the epigenetic analysis of patient samples and found that specific methylation sites in prostate cancer can be used as molecular markers for early diagnosis of prostate cancer. After further urine DNA test, the sensitivity and specificity of this site for prostate cancer diagnosis is much better than the traditional method, and the method is non-invasive body fluid detection, which has great clinical significance and application value, and fills up. Domestic blank, with international leading level. The researcher Sun Yingli and the president of the Second Military Medical University, Sun Yinghao, said that the study is of great significance for the clinical non-invasive diagnosis of prostate cancer. The research was funded by the Ministry of Science and Technology Key Basic Research and Development Program (973), the Chinese Academy of Sciences' Strategic Pilot Project, and the National Natural Science Foundation. Recently, Wuxi Shenrui Biological Products Co., Ltd. and the Beijing Institute of Genomics of the Chinese Academy of Sciences signed a patent transfer contract for the application of “specific methylation sites in the Y chromosome as a diagnostic marker for cancerâ€, and obtained the global exclusive patent. right. They will rely on the genome of the Chinese Academy of Sciences to carry out the early non-invasive genetic testing technology and product industrialization of prostate cancer. Shenzhen Sunson Tech Co., Ltd , https://www.sunsonkiosk.com